Epigenetic Editing Shuts Down Hepatitis B Without Cutting DNA
A CRISPR enzyme that tags viral genes instead of slicing them shows strong preclinical results — and has entered human trials.
More than 250 million people live with chronic hepatitis B. Existing drugs suppress the virus but rarely eradicate the reservoir of viral DNA hiding in liver cells.
Nature reported that nChroma Bio and collaborators have published evidence in Nature Biomedical Engineering that an epigenetic editor, CRMA-1001, can silence both free-ranging HBV mini-chromosomes and viral DNA stitched into the host genome by adding methyl tags — without cutting DNA.
Results in human liver cells and mice were described as impressive after a single injection. Monkey studies showed only minimal, temporary side effects. A clinical trial is already underway in Hong Kong and New Zealand; the first participant was dosed in January.
DNA-cutting gene editors raise cancer-risk concerns when viral sequences are integrated into the host genome. Epigenetic silencing is an attempt to shut the faucet rather than mop the floor.
Key Facts
- Chronic HBV: more than 250 million people worldwide
- Therapy: catalytically dead Cas9 plus guide RNAs in a lipid nanoparticle
- First human dosed January 2026
- Paper: Nature Biomedical Engineering, 21 September 2026
Why This Matters
Standard antivirals almost never clear the viral reservoir. A one-time epigenetic silencer, if it works in people, would be a path to a functional cure for one of the world's biggest chronic infections.
What We Don't Know Yet
The Nature paper is preclinical. Human efficacy is not yet proven. Durability of silencing in humans is the open question. Functional cure, not sterilising cure, is the realistic bar.
Sources: Nature · Nature Biomedical Engineering
Published 21 September 2026 · Category: Science & Technology